Considering Fabry, but Diagnosing MPS I: Difficulties in the Diagnostic Process
- 30 October 2012
- book chapter
- Published by Springer Nature
- Vol. 9, 117-120
Abstract
Recent studies have indicated that a proportion of patients with renal failure, left ventricular hypertrophy, or cryptogenic stroke have sequence variants in their aGal A gene (Fabry disease), which has resulted in an increase in diagnostic activities for this disorder. The diagnostic process for lysosomal storage disorders may result in findings of unknown clinical significance. Here we report such an unexpected outcome. A 32-year-old male presented at the emergency department because of a transient ischemic attack. Extensive investigations revealed no cause and an initial diagnosis of cryptogenic stroke was made. Subsequently, aGal A activity was measured in a bloodspot and was shown to be normal, but the activity of alpha-L-iduronidase (IDUA), used as reference enzyme, was unexpectedly low: 0.5 umol/L (ref = 1.7-14.3). A diagnosis of IDUA deficiency, mucopolysaccharidosis type 1S or Scheie disease was considered. IDUA gene analysis revealed two homozygous sequence alterations: a silent sequence change (979C > T) in exon 7 (N297N) and an unknown missense mutation 875A > T (R263W). Physical examination was completely normal, without clinical signs of mucopolysaccharidosis type I (MPS I). Leukocyte IDUA activity was also low: 2.1 nmol/mg prot/h (ref = 14-40 nmol prot/h), but higher than the patient range of <0.1 nmol/mg prot/h. Urinary glycosaminoglycan levels were normal both quantitatively and qualitatively. It was concluded that there was low IDUA activity without clinical symptoms and the diagnosis of mucopolysaccharidosis I was discarded. The diagnostic process for lysosomal storage disorders may result in biochemical abnormalities of unknown clinical significance. Early evaluation by a specialist in inborn errors of metabolism may help to avoid anxiety in patients and unnecessary additional analyses.Keywords
This publication has 19 references indexed in Scilit:
- Endothelial function in children and adolescents with mucopolysaccharidosisJournal of Inherited Metabolic Disease, 2012
- Effects of enzyme replacement therapy in Fabry disease—A comprehensive review of the medical literatureGenetics in Medicine, 2010
- The burden of incidental findings in clinical practice in a tertiary care centerEuropean Journal of Internal Medicine, 2010
- Screening for Fabry disease in high-risk populations: a systematic reviewJournal of Medical Genetics, 2009
- Fabry's diseaseThe Lancet, 2008
- Mucopolysaccharidosis I under enzyme replacement therapy with laronidase—A mortality case with autopsy reportJournal of Inherited Metabolic Disease, 2005
- Fabry disease: enzymatic diagnosis in dried blood spots on filter paperClinica Chimica Acta, 2001
- Molecular genetic defect underlying alpha-L-iduronidase pseudodeficiency.1996
- A pseudodeficiency allele common in non-Jewish Tay-Sachs carriers: implications for carrier screening.1992
- A family with pseudodeficiency of acid α‐glucosidaseClinical Genetics, 1988